Samuel Collins

Samuel Collins is a seasoned medical professional with extensive experience in clinical development and leadership in rare genetic neurodevelopmental disorders and rare diseases. Currently serving as the Consultant Chief Medical Officer at Mahzi Therapeutics, Samuel provides clinical oversight for gene therapy programs and due diligence for in-licensing activities. Previously, Samuel held key roles at Actio Biosciences, Inc., and Edgewise Therapeutics, leading clinical strategies and overseeing pivotal studies in various therapeutic areas. With a robust educational background, including an MBA and PhD, Samuel has a strong foundation in both medicine and business, complemented by a track record of successful stakeholder engagement, regulatory strategy, and patient advocacy throughout a diverse career in both academic and industry settings.